Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

N6-Isopentenyladenosine Inhibits Colorectal Cancer and Improves Sensitivity to 5-Fluorouracil-Targeting FBXW7 Tumor Suppressor.

Fiore D, Piscopo C, Proto MC, Vasaturo M, Dal Piaz F, Fusco BM, Pagano C, Laezza C, Bifulco M, Gazzerro P.

Cancers (Basel). 2019 Sep 28;11(10). pii: E1456. doi: 10.3390/cancers11101456.

2.

New sesquiterpenes from Asteriscus graveolens.

Achoub H, Mencherini T, Esposito T, Luca R, Aquino R, Gazzerro P, Zaiter L, Benayache F, Benayache S.

Nat Prod Res. 2019 Sep 23:1-9. doi: 10.1080/14786419.2019.1666390. [Epub ahead of print]

PMID:
31542956
3.

Tetra-substituted pyrrole derivatives act as potent activators of p53 in melanoma cells.

Proto MC, Fiore D, Forte G, Cuozzo P, Ramunno A, Fattorusso C, Gazzerro P, Pascale M, Franceschelli S.

Invest New Drugs. 2019 Jun 26. doi: 10.1007/s10637-019-00813-4. [Epub ahead of print]

PMID:
31240514
4.

PR/SET Domain Family and Cancer: Novel Insights from the Cancer Genome Atlas.

Sorrentino A, Federico A, Rienzo M, Gazzerro P, Bifulco M, Ciccodicola A, Casamassimi A, Abbondanza C.

Int J Mol Sci. 2018 Oct 19;19(10). pii: E3250. doi: 10.3390/ijms19103250.

5.

Pressurized hot water extraction of bioactive compounds from artichoke by-products.

Pagano I, Piccinelli AL, Celano R, Campone L, Gazzerro P, Russo M, Rastrelli L.

Electrophoresis. 2018 May 18. doi: 10.1002/elps.201800063. [Epub ahead of print]

PMID:
29775214
6.

Colon Cancer Survival and Statins: What More Evidence Do We Need?

Bifulco M, Gazzerro P.

Gastroenterology. 2018 Apr;154(5):1545-1546. doi: 10.1053/j.gastro.2017.06.071. Epub 2018 Mar 8. No abstract available.

PMID:
29526725
7.

Heliotropium bacciferum Forssk. (Boraginaceae) extracts: chemical constituents, antioxidant activity and cytotoxic effect in human cancer cell lines.

Aïssaoui H, Mencherini T, Esposito T, De Tommasi N, Gazzerro P, Benayache S, Benayache F, Mekkiou R.

Nat Prod Res. 2019 Jun;33(12):1813-1818. doi: 10.1080/14786419.2018.1437433. Epub 2018 Feb 12.

PMID:
29430949
8.

Rimonabant Kills Colon Cancer Stem Cells without Inducing Toxicity in Normal Colon Organoids.

Fiore D, Ramesh P, Proto MC, Piscopo C, Franceschelli S, Anzelmo S, Medema JP, Bifulco M, Gazzerro P.

Front Pharmacol. 2018 Jan 4;8:949. doi: 10.3389/fphar.2017.00949. eCollection 2017.

9.

Synthesis and biological evaluation of Santacruzamate-A based analogues.

Randino R, Gazzerro P, Mazitschek R, Rodriquez M.

Bioorg Med Chem. 2017 Dec 15;25(24):6486-6491. doi: 10.1016/j.bmc.2017.10.026. Epub 2017 Oct 20.

PMID:
29100734
10.

Deregulated expression and activity of Farnesyl Diphosphate Synthase (FDPS) in Glioblastoma.

Abate M, Laezza C, Pisanti S, Torelli G, Seneca V, Catapano G, Montella F, Ranieri R, Notarnicola M, Gazzerro P, Bifulco M, Ciaglia E.

Sci Rep. 2017 Oct 26;7(1):14123. doi: 10.1038/s41598-017-14495-6.

11.

N6-isopentenyladenosine dual targeting of AMPK and Rab7 prenylation inhibits melanoma growth through the impairment of autophagic flux.

Ranieri R, Ciaglia E, Amodio G, Picardi P, Proto MC, Gazzerro P, Laezza C, Remondelli P, Bifulco M, Pisanti S.

Cell Death Differ. 2018 Feb;25(2):353-367. doi: 10.1038/cdd.2017.165. Epub 2017 Oct 13.

12.

Inhibition of Wnt/β-Catenin pathway and Histone acetyltransferase activity by Rimonabant: a therapeutic target for colon cancer.

Proto MC, Fiore D, Piscopo C, Franceschelli S, Bizzarro V, Laezza C, Lauro G, Feoli A, Tosco A, Bifulco G, Sbardella G, Bifulco M, Gazzerro P.

Sci Rep. 2017 Sep 15;7(1):11678. doi: 10.1038/s41598-017-11688-x.

13.

Recognition by natural killer cells of N6-isopentenyladenosine-treated human glioma cell lines.

Ciaglia E, Laezza C, Abate M, Pisanti S, Ranieri R, D'alessandro A, Picardi P, Gazzerro P, Bifulco M.

Int J Cancer. 2018 Jan 1;142(1):176-190. doi: 10.1002/ijc.31036. Epub 2017 Sep 21.

14.

Immuno-Modulatory and Anti-Inflammatory Effects of Dihydrogracilin A, a Terpene Derived from the Marine Sponge Dendrilla membranosa.

Ciaglia E, Malfitano AM, Laezza C, Fontana A, Nuzzo G, Cutignano A, Abate M, Pelin M, Sosa S, Bifulco M, Gazzerro P.

Int J Mol Sci. 2017 Jul 28;18(8). pii: E1643. doi: 10.3390/ijms18081643.

15.

The isoprenoid derivative N6 -benzyladenosine CM223 exerts antitumor effects in glioma patient-derived primary cells through the mevalonate pathway.

Ciaglia E, Grimaldi M, Abate M, Scrima M, Rodriquez M, Laezza C, Ranieri R, Pisanti S, Ciuffreda P, Manera C, Gazzerro P, D'Ursi AM, Bifulco M.

Br J Pharmacol. 2017 Jul;174(14):2287-2301. doi: 10.1111/bph.13824. Epub 2017 Jun 11.

16.

Antiglioma effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, through the downregulation of epidermal growth factor receptor.

Ciaglia E, Abate M, Laezza C, Pisanti S, Vitale M, Seneca V, Torelli G, Franceschelli S, Catapano G, Gazzerro P, Bifulco M.

Int J Cancer. 2017 Feb 15;140(4):959-972. doi: 10.1002/ijc.30505. Epub 2016 Nov 16.

17.

Chemical profile and cellular antioxidant activity of artichoke by-products.

Pagano I, Piccinelli AL, Celano R, Campone L, Gazzerro P, De Falco E, Rastrelli L.

Food Funct. 2016 Dec 7;7(12):4841-4850.

PMID:
27809319
18.

HRMS Profile of a Hazelnut Skin Proanthocyanidin-rich Fraction with Antioxidant and Anti-Candida albicans Activities.

Piccinelli AL, Pagano I, Esposito T, Mencherini T, Porta A, Petrone AM, Gazzerro P, Picerno P, Sansone F, Rastrelli L, Aquino RP.

J Agric Food Chem. 2016 Jan 27;64(3):585-95. doi: 10.1021/acs.jafc.5b05404. Epub 2016 Jan 15.

PMID:
26739867
19.

p53 regulates the mevalonate pathway in human glioblastoma multiforme.

Laezza C, D'Alessandro A, Di Croce L, Picardi P, Ciaglia E, Pisanti S, Malfitano AM, Comegna M, Faraonio R, Gazzerro P, Bifulco M.

Cell Death Dis. 2015 Oct 15;6:e1909. doi: 10.1038/cddis.2015.279.

20.

Antitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with Oxaliplatin and 5-FU in colorectal cancer cells.

Fiore D, Proto MC, Pisanti S, Picardi P, Pagano Zottola AC, Butini S, Gemma S, Casagni A, Laezza C, Vitale M, Ligresti A, Di Marzo V, Zisterer DM, Nathwani S, Williams DC, Campiani G, Gazzerro P, Bifulco M.

Cancer Biol Ther. 2016 Aug 2;17(8):849-58. doi: 10.1080/15384047.2015.1078028.

21.

Annurca peel extract: from the chemical composition, through the functional activity, to the formulation and characterisation of a topical oil-in-water emulsion.

Sansone F, Esposito T, Mencherini T, Piccinelli AL, Gazzerro P, Picerno P, Russo P, Del Gaudio P, Essolito M, Campiglia P, Aquino RP.

Nat Prod Res. 2016 Jun;30(12):1398-403. doi: 10.1080/14786419.2015.1062005. Epub 2015 Jul 27.

PMID:
26211432
22.

Cannabinoid receptor CB1 regulates STAT3 activity and its expression dictates the responsiveness to SR141716 treatment in human glioma patients' cells.

Ciaglia E, Torelli G, Pisanti S, Picardi P, D'Alessandro A, Laezza C, Malfitano AM, Fiore D, Pagano Zottola AC, Proto MC, Catapano G, Gazzerro P, Bifulco M.

Oncotarget. 2015 Jun 20;6(17):15464-81.

23.

New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor agonists with anticancer and immuno-modulatory activity.

Manera C, Malfitano AM, Parkkari T, Lucchesi V, Carpi S, Fogli S, Bertini S, Laezza C, Ligresti A, Saccomanni G, Savinainen JR, Ciaglia E, Pisanti S, Gazzerro P, Di Marzo V, Nieri P, Macchia M, Bifulco M.

Eur J Med Chem. 2015 Jun 5;97:10-8. doi: 10.1016/j.ejmech.2015.04.034. Epub 2015 Apr 24.

PMID:
25935384
24.

Anandamide drives cell cycle progression through CB1 receptors in a rat model of synchronized liver regeneration.

Pisanti S, Picardi P, Pallottini V, Martini C, Petrosino S, Proto MC, Vitale M, Laezza C, Gazzerro P, Di Marzo V, Bifulco M.

J Cell Physiol. 2015 Dec;230(12):2905-14. doi: 10.1002/jcp.24959.

PMID:
25684344
25.

Structural evidence of N6-isopentenyladenosine as a new ligand of farnesyl pyrophosphate synthase.

Scrima M, Lauro G, Grimaldi M, Di Marino S, Tosco A, Picardi P, Gazzerro P, Riccio R, Novellino E, Bifulco M, Bifulco G, D'Ursi AM.

J Med Chem. 2014 Sep 25;57(18):7798-803. doi: 10.1021/jm500869x. Epub 2014 Sep 15.

PMID:
25184810
26.

N6-isopentenyladenosine affects cytotoxic activity and cytokines production by IL-2 activated NK cells and exerts topical anti-inflammatory activity in mice.

Ciaglia E, Pisanti S, Picardi P, Laezza C, Sosa S, Tubaro A, Vitale M, Gazzerro P, Malfitano AM, Bifulco M.

Pharmacol Res. 2014 Nov;89:1-10. doi: 10.1016/j.phrs.2014.07.003. Epub 2014 Jul 22.

PMID:
25063359
27.

Statins in neurological disorders: an overview and update.

Malfitano AM, Marasco G, Proto MC, Laezza C, Gazzerro P, Bifulco M.

Pharmacol Res. 2014 Oct;88:74-83. doi: 10.1016/j.phrs.2014.06.007. Epub 2014 Jun 19. Review.

PMID:
24954580
28.

Antiangiogenic effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, mediated by AMPK activation.

Pisanti S, Picardi P, Ciaglia E, Margarucci L, Ronca R, Giacomini A, Malfitano AM, Casapullo A, Laezza C, Gazzerro P, Bifulco M.

FASEB J. 2014 Mar;28(3):1132-44. doi: 10.1096/fj.13-238238. Epub 2013 Nov 21.

PMID:
24265487
29.

Immune-modulation and properties of absorption and blood brain barrier permeability of 1,8-naphthyridine derivatives.

Malfitano AM, Laezza C, Saccomanni G, Tuccinardi T, Manera C, Martinelli A, Ciaglia E, Pisanti S, Vitale M, Gazzerro P, Bifulco M.

J Neuroimmune Pharmacol. 2013 Dec;8(5):1077-86. doi: 10.1007/s11481-013-9494-0. Epub 2013 Oct 1.

PMID:
24081326
30.

PBOX-15 induces apoptosis and improves the efficacy of oxaliplatin in human colorectal cancer cell lines.

Gangemi G, Gazzerro P, Fiore D, Proto MC, Butini S, Gemma S, Casagni A, Laezza C, Vitale M, Ligresti A, Di Marzo V, Zisterer DM, Nathwani S, Clive Williams D, Campiani G, Bifulco M.

Eur J Pharmacol. 2013 Aug 15;714(1-3):379-87. doi: 10.1016/j.ejphar.2013.07.011. Epub 2013 Jul 16. Retraction in: Eur J Pharmacol. 2014 Apr 5;728:190.

PMID:
23872382
31.

N6-isopentenyladenosine, an endogenous isoprenoid end product, directly affects cytotoxic and regulatory functions of human NK cells through FDPS modulation.

Ciaglia E, Pisanti S, Picardi P, Laezza C, Malfitano AM, D'Alessandro A, Gazzerro P, Vitale M, Carbone E, Bifulco M.

J Leukoc Biol. 2013 Dec;94(6):1207-19. doi: 10.1189/jlb.0413190. Epub 2013 Jul 11.

PMID:
23847096
32.

The right to care and the expectations of society--controversial stem cell therapy in Italy.

Bifulco M, Gazzerro P.

EMBO Rep. 2013 Jul;14(7):578. doi: 10.1038/embor.2013.71. Epub 2013 Jun 4. No abstract available.

33.

Effects on immune cells of a new 1,8-naphthyridin-2-one derivative and its analogues as selective CB2 agonists: implications in multiple sclerosis.

Malfitano AM, Laezza C, D'Alessandro A, Procaccini C, Saccomanni G, Tuccinardi T, Manera C, Macchia M, Matarese G, Gazzerro P, Bifulco M.

PLoS One. 2013 May 1;8(5):e62511. doi: 10.1371/journal.pone.0062511. Print 2013.

34.

Statins and cancer in gastroenterology: new insight?

Gazzerro P, Bifulco M.

Gastroenterology. 2013 Jun;144(7):1572-3. doi: 10.1053/j.gastro.2013.03.055. Epub 2013 Apr 28. No abstract available.

PMID:
23628277
35.

Statins and cancer-related mortality: an open question.

Gazzerro P, Ciaglia E, Bifulco M.

Basic Clin Pharmacol Toxicol. 2013 Aug;113(2):73-4. doi: 10.1111/bcpt.12080. Epub 2013 May 25. No abstract available.

36.

Cannabinoid type 1 receptor gene polymorphism and macronutrient intake.

Caruso MG, Gazzerro P, Notarnicola M, Cisternino AM, Guerra V, Misciagna G, Laezza C, Bifulco M.

J Nutrigenet Nutrigenomics. 2012;5(6):305-13. doi: 10.1159/000343563. Epub 2012 Nov 27.

37.

Anandamide inhibits the Wnt/β-catenin signalling pathway in human breast cancer MDA MB 231 cells.

Laezza C, D'Alessandro A, Paladino S, Maria Malfitano A, Chiara Proto M, Gazzerro P, Pisanti S, Santoro A, Ciaglia E, Bifulco M; Endocannabinoid Research Group.

Eur J Cancer. 2012 Nov;48(16):3112-22. doi: 10.1016/j.ejca.2012.02.062. Epub 2012 Mar 14.

PMID:
22425263
38.

The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour growth in mice.

Malfitano AM, Laezza C, Galgani M, Matarese G, D'Alessandro A, Gazzerro P, Bifulco M.

Pharmacol Res. 2012 Mar;65(3):365-71. doi: 10.1016/j.phrs.2011.11.008. Epub 2011 Nov 22.

PMID:
22123497
39.

Pharmacological actions of statins: a critical appraisal in the management of cancer.

Gazzerro P, Proto MC, Gangemi G, Malfitano AM, Ciaglia E, Pisanti S, Santoro A, Laezza C, Bifulco M.

Pharmacol Rev. 2012 Jan;64(1):102-46. doi: 10.1124/pr.111.004994. Epub 2011 Nov 21. Review.

PMID:
22106090
40.

Identification of a functional estrogen-responsive enhancer element in the promoter 2 of PRDM2 gene in breast cancer cell lines.

Abbondanza C, De Rosa C, D'Arcangelo A, Pacifico M, Spizuoco C, Piluso G, Di Zazzo E, Gazzerro P, Medici N, Moncharmont B, Puca GA.

J Cell Physiol. 2012 Mar;227(3):964-75. doi: 10.1002/jcp.22803.

PMID:
21503890
41.

Genetic and pharmacologic inactivation of cannabinoid CB1 receptor inhibits angiogenesis.

Pisanti S, Picardi P, Prota L, Proto MC, Laezza C, McGuire PG, Morbidelli L, Gazzerro P, Ziche M, Das A, Bifulco M.

Blood. 2011 May 19;117(20):5541-50. doi: 10.1182/blood-2010-09-307355. Epub 2011 Apr 1.

PMID:
21460248
42.

Interaction of endocannabinoid system and steroid hormones in the control of colon cancer cell growth.

Proto MC, Gazzerro P, Di Croce L, Santoro A, Malfitano AM, Pisanti S, Laezza C, Bifulco M.

J Cell Physiol. 2012 Jan;227(1):250-8. doi: 10.1002/jcp.22727.

PMID:
21412772
43.

Update on the endocannabinoid system as an anticancer target.

Malfitano AM, Ciaglia E, Gangemi G, Gazzerro P, Laezza C, Bifulco M.

Expert Opin Ther Targets. 2011 Mar;15(3):297-308. doi: 10.1517/14728222.2011.553606. Epub 2011 Jan 19. Review.

PMID:
21244344
44.

Rimonabant-induced apoptosis in leukemia cell lines: activation of caspase-dependent and -independent pathways.

Gallotta D, Nigro P, Cotugno R, Gazzerro P, Bifulco M, Belisario MA.

Biochem Pharmacol. 2010 Aug 1;80(3):370-80. doi: 10.1016/j.bcp.2010.04.023. Epub 2010 Apr 24.

PMID:
20417624
45.

Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and of Ras farnesylation mediate antitumor effects of anandamide in human breast cancer cells.

Laezza C, Malfitano AM, Proto MC, Esposito I, Gazzerro P, Formisano P, Pisanti S, Santoro A, Caruso MG, Bifulco M.

Endocr Relat Cancer. 2010 May 18;17(2):495-503. doi: 10.1677/ERC-10-0009. Print 2010 Jun.

PMID:
20304978
46.

Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression.

Monteleone P, Bifulco M, Maina G, Tortorella A, Gazzerro P, Proto MC, Di Filippo C, Monteleone F, Canestrelli B, Buonerba G, Bogetto F, Maj M.

Pharmacol Res. 2010 May;61(5):400-4. doi: 10.1016/j.phrs.2010.01.002. Epub 2010 Jan 18.

PMID:
20080186
47.

Rimonabant (SR141716) induces metabolism and acquisition of fertilizing ability in human sperm.

Aquila S, Guido C, Santoro A, Gazzerro P, Laezza C, Baffa MF, Andò S, Bifulco M.

Br J Pharmacol. 2010 Feb;159(4):831-41. doi: 10.1111/j.1476-5381.2009.00570.x. Epub 2010 Jan 8. Erratum in: Br J Pharmacol. 2017 Aug;174(16):2797.

48.

Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin.

Gazzerro P, Malfitano AM, Proto MC, Santoro A, Pisanti S, Caruso MG, Notarnicola M, Messa C, Laezza C, Misso G, Caraglia M, Bifulco M.

Oncol Rep. 2010 Jan;23(1):171-5.

PMID:
19956878
49.

Association of CNR1 and FAAH endocannabinoid gene polymorphisms with anorexia nervosa and bulimia nervosa: evidence for synergistic effects.

Monteleone P, Bifulco M, Di Filippo C, Gazzerro P, Canestrelli B, Monteleone F, Proto MC, Di Genio M, Grimaldi C, Maj M.

Genes Brain Behav. 2009 Oct;8(7):728-32. doi: 10.1111/j.1601-183X.2009.00518.x. Epub 2009 Jun 26.

50.

Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colon.

Santoro A, Pisanti S, Grimaldi C, Izzo AA, Borrelli F, Proto MC, Malfitano AM, Gazzerro P, Laezza C, Bifulco M.

Int J Cancer. 2009 Sep 1;125(5):996-1003. doi: 10.1002/ijc.24483.

Supplemental Content

Loading ...
Support Center